| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥444.1B | ¥428.1B | +3.7% |
| Operating Income | ¥98.2B | ¥99.1B | -0.8% |
| Ordinary Income | ¥96.1B | ¥99.4B | -3.4% |
| Net Income | ¥68.2B | ¥70.7B | -3.5% |
| ROE | 10.8% | 11.8% | - |
FY2026 Q3 results show revenue of 444.1B yen (YoY +3.7%), operating income of 98.2B yen (-0.8%), ordinary income of 96.1B yen (-3.4%), and net income of 68.2B yen (-3.5%). The quarter demonstrated revenue growth but faced profitability headwinds from gross margin compression of 80 basis points to 59.7%, selling, general and administrative expenses growth of 4.3% outpacing revenue growth, and deteriorating non-operating balance. Operating margin contracted 101 basis points to 22.1% despite revenue expansion. Full-year guidance remains unchanged at revenue of 593B yen (+4.8%), operating income of 129B yen (+4.7%), and net income of 93.5B yen, implying Q4 acceleration in profitability metrics.
[Profitability] ROE stands at 10.8%, maintained through a combination of net profit margin of 15.4%, asset turnover of 0.584, and financial leverage of 1.20x. Gross profit margin compressed to 59.7% from 60.5% YoY, declining 80 basis points due to product mix shifts and cost pressures. Operating margin contracted to 22.1% from 23.1% YoY, declining 101 basis points as SG&A expenses grew 4.3% compared to revenue growth of 3.7%. Net profit margin decreased 116 basis points to 15.4% from 16.5% YoY, reflecting the cumulative impact of gross margin erosion, expense growth, and non-operating deterioration. [Cash Quality] Cash and deposits of 86.4B yen provide 2.7x coverage of short-term debt of 32.0B yen, with net cash position of 54.4B yen supporting strong liquidity. Working capital expansion occurred through inventory increase of 7.4% to 192.9B yen and accounts receivable growth of 9.3% to 151.2B yen, while accounts payable decreased. [Investment Efficiency] Total asset turnover of 0.584 reflects the capital-intensive nature of medical device inventory requirements. Inventory to total assets ratio increased, requiring monitoring of turnover efficiency. [Financial Health] Equity ratio of approximately 83.1% with total equity of 632.0B yen against total assets of 760.6B yen demonstrates exceptionally strong capitalization. Current ratio of 367.6% and quick ratio of 208.8% indicate robust liquidity. Debt-to-equity ratio of 0.05x and debt-to-capital ratio of 4.8% reflect conservative financial structure.
Cash and deposits decreased 21.5% YoY to 86.4B yen from 110.1B yen, primarily driven by working capital absorption. Inventory increased 7.4% to 192.9B yen while accounts receivable expanded 9.3% to 151.2B yen, creating cash outflow pressure. Conversely, accounts payable decreased to 39.2B yen, further constraining operating cash generation. The net cash position remains healthy at 54.4B yen (cash of 86.4B yen minus total interest-bearing debt of 32.0B yen), providing substantial buffer. Treasury stock account moved from negative 57.8B yen to negative 12.1B yen, a 79.1% improvement suggesting share retirement or disposal activities that improved capital efficiency with limited cash impact. Despite working capital headwinds, the company maintains short-term debt coverage of 2.7x, indicating adequate liquidity management. The increase in working capital assets reflects inventory build-up for stable medical device supply and accounts receivable expansion from revenue growth, though turnover improvement remains a priority for enhanced cash conversion.
Ordinary income of 96.1B yen versus operating income of 98.2B yen shows a net non-operating loss of approximately 2.1B yen, representing a deterioration from prior year when non-operating items contributed positively. Non-operating expenses expanded to 3.87B yen while non-operating income declined to 1.7B yen, creating headwinds at the ordinary income level. Extraordinary losses increased to 1.96B yen from 0.36B yen YoY, including 1.08B yen in head office relocation expenses, though these represent non-recurring costs. The effective tax rate of 27.7% remains within standard ranges, with the tax burden coefficient of 0.723 and interest burden coefficient of 0.960 both indicating healthy earnings structure. Operating income represents 22.1% of revenue, demonstrating strong core profitability despite margin contraction. The earnings base remains cash-backed as evidenced by substantial cash holdings relative to liabilities, though working capital expansion absorbed some operating cash generation during the quarter. Core operating performance drives the majority of earnings with limited reliance on non-recurring gains, supporting sustainable earnings quality.
Margin compression risk from product mix evolution and procurement cost inflation, evidenced by gross margin declining 80 basis points to 59.7% with SG&A expense growth of 4.3% outpacing revenue growth of 3.7%, creating operating leverage challenges. Working capital management risk as inventory increased 7.4% and accounts receivable expanded 9.3% while accounts payable decreased, absorbing cash and potentially indicating slower turnover that could lead to obsolescence or collection issues if medical device demand weakens. Regulatory and reimbursement pricing risk inherent to the medical device sector, where government healthcare policy changes could pressure product pricing and profitability, particularly relevant given the company's dependence on cardiovascular and other specialized medical equipment segments where reimbursement rates face periodic revision.
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates exceptional financial strength relative to the trading industry peer group. Profitability metrics substantially exceed sector norms, with ROE of 10.8% versus industry median of 4.0% (2025-Q3, n=14), operating margin of 22.1% versus industry median of 2.8%, and net profit margin of 15.4% versus industry median of 1.8%. These differentials reflect the company's positioning in specialized medical device distribution with higher value-add services compared to general trading businesses. Financial health indicators also surpass industry standards, with equity ratio of approximately 83% versus industry median of 47.3% and current ratio of 367.6% versus industry median of 1.84x. The net cash position contrasts sharply with industry median net debt of -2.14x EBITDA. Revenue growth of 3.7% exceeds industry median of 1.1%, indicating market share gains or favorable end-market exposure. ROA of approximately 9.0% significantly outperforms industry median of 2.2%. The company operates with materially superior profitability and financial stability compared to broad trading sector peers, reflecting specialized healthcare distribution economics rather than commodity trading dynamics. ※ Industry: Trading (14 companies), Comparison: FY2025-Q3, Source: Proprietary analysis
Revenue momentum remains intact at 3.7% YoY growth with full-year guidance of 4.8% maintained, though profitability faces near-term headwinds from gross margin compression of 80 basis points and SG&A expense growth outpacing revenue. The deterioration in operating margin to 22.1% (negative 101 basis points) and net margin to 15.4% (negative 116 basis points) represents a reversal from typical operating leverage, requiring management focus on cost efficiency and pricing power to restore margin expansion. Financial fortress balance sheet with 83% equity ratio, net cash of 54.4B yen, and liquidity ratios exceeding 200% provides substantial buffer for navigating margin pressure and supports sustainable dividend policy at 55.4% payout ratio. The company's profitability metrics of 10.8% ROE, 22.1% operating margin, and 15.4% net margin remain exceptional relative to trading industry medians of 4.0%, 2.8%, and 1.8% respectively, indicating durable competitive advantages in specialized medical device distribution despite temporary margin headwinds. Working capital absorption from inventory buildup of 7.4% and receivables growth of 9.3% warrant monitoring for turnover efficiency, though the strategic rationale of ensuring stable medical device supply and maintaining customer relationships provides context for these trends.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.